Endeavor BioMedicines is a clinical-stage biotechnology company that develops new treatments targeting the underlying causes of pulmonary fibrosis. It produces taladegib, a small-molecule inhibitor of the Hedgehog signaling pathway for treating idiopathic pulmonary fibrosis.